Key facts
- Notable investors include Innovate UK, Scottish Enterprise, The FSE Group, NZIP Acceleration, Horizon 2020 — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Ingenza
- ·The full record, as it builds
Funding rounds
No funding rounds for Ingenza are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ingenza
Operator of a biotechnology company intended to generate innovative biobased systems for a diverse range of customer problems. The company's services provide efficient, scalable bioprocesses for the manufacture of chemicals, biologics, pharmaceuticals, and biofuels, from sustainable sources, and have assembled integrated teams of scientists bringing together expertise across synthetic chemistry, informatics, molecular genetics, biochemistry, and fermentation scale-up, enabling clients to shorten the bioengineering design and test cycle and successfully construct bioprocesses.
- Sector
- Healthcare
- HQ
- Penicuik, United Kingdom
- Founded
- 2002
- Employees
- 50
- Website
- ingenza.com/
- Ownership
- Privately Held (backing)
Ingenza doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ingenza shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ingenza in its N-PORT filings yet. We sweep new filings monthly.